Overview of Azole(DIAL PHARMA)

The following provides a concise overview of Azole (DIAL PHARMA), focusing on its identity, composition, class, and general purpose as an essential medicine.

Property	Description
Active Ingredient	Albendazole (INN)
Form	Oral tablets, Oral suspension
Pharmacological Class	Anthelmintic (Benzimidazole derivative)
Common Use	Combating parasitic worm infestations
Origin	Synthetic compound

Azole (DIAL PHARMA): Identity and Pharmacological Classification

Azole (DIAL PHARMA) is a prescription-only medicine from DIAL PHARMA, featuring the active ingredient Albendazole (INN). It is classified as an anthelmintic agent, belonging to the Benzimidazole chemical subclass, which is utilized for its broad activity against parasitic worms. The Albendazole substance is a synthetic compound utilized for its effectiveness against helminths. It is recognized as a vital therapeutic agent for the treatment of these conditions globally.

Composition, Origin, and Available Forms

The medication contains Albendazole as a single active ingredient. Its chemical origin is purely synthetic, having been derived from the Benzimidazole structure. Azole (DIAL PHARMA) is formulated for administration via the oral route and is available in two primary preparations: solid oral tablets (which may be chewable or film-coated) and an oral suspension. The provision of both forms is crucial for patient adherence across different age groups.

General Purpose and High-Level Action

The general purpose of Azole (DIAL PHARMA) is to serve as a broad-spectrum anti-parasitic agent, typically used to target and eliminate various susceptible parasitic worms. Its fundamental action, which is widely recognized in scientific literature, involves interfering with the parasite's internal cellular structures and inhibiting its uptake of essential nutrients like glucose. This mechanism leads to the systemic elimination of the parasites, providing the primary benefit of clearing the infection.

Regulatory References

World Health Organization (WHO) Essential Medicines Lists

What side effects are possible with Azole(DIAL PHARMA)?

Possible Side Effects and Safety Information

The safety profile of Azole (DIAL PHARMA), which contains Albendazole, is structured by official regulatory documents based on frequency and affected physiological systems. Adverse reactions are classified using standard frequency categories, such as Very Common and Common events.

Very Common adverse reactions, which occur in 1/10 patients, include mild to moderate elevations of hepatic enzymes and headache, particularly during longer-duration treatment regimens. Common effects, occurring in 1/100 patients, generally involve gastrointestinal disturbances (such as abdominal pain, nausea, and vomiting) and reversible alopecia.

Serious Adverse Reactions and Systemic Concerns

The regulatory profile identifies specific serious systemic concerns, primarily associated with prolonged, higher-dose treatments. These include potentially fatal events such as bone marrow suppression (leading to conditions like pancytopenia) and severe hepatotoxicity (including acute liver failure). Effects on the nervous system, such as seizures and increased intracranial pressure, may occur soon after initiating therapy for neurocysticercosis due to the inflammatory response to parasite death.

Regulatory Safety Notes

Official labeling mandates periodic monitoring of both complete blood cell counts and liver function tests throughout therapy due to the risk of severe blood and liver abnormalities. The medicine is contraindicated in individuals with a known hypersensitivity to the benzimidazole class of compounds.

Specific safety statements advise females of reproductive potential to use effective contraception, as the substance is classified as potentially embryo-fetal toxic. Patients with pre-existing hepatic disease are also noted to be at an increased risk for certain severe adverse reactions and require closer observation.

Overdose and Emergency Response

Overdose and When to Seek Help for Azole (Albendazole)

The regulatory profile for Azole (Albendazole) specifies that immediate medical attention must be sought in the event of any suspected or confirmed overdose. This requirement is non-negotiable across official government guidance, necessitating contact with emergency services or a poison control center immediately.

Documented Manifestations and Serious Outcomes

Official labeling describes overdose by listing the documented clinical manifestations observed in cases of overexposure. These symptoms are generally extensions of common adverse reactions, but occurring at a greater severity:

Gastrointestinal and CNS Effects: Manifestations include diarrhea, vomiting, nausea, lethargy, dizziness, and visual disturbances.
Physiological Findings: Official reports note tachycardia (increased heart rate) and laboratory evidence of elevated hepatic transaminases (indicating liver stress).

Official Management and Antidote Status

Management of overdosage must follow the official procedures described in prescribing information. The primary strategy mandated is symptomatic and supportive treatment, focusing on maintaining the patient's vital functions. Regulatory documents explicitly state that no specific antidote is known for Albendazole overdose. Interventions such as gastric lavage and the administration of activated charcoal are officially described as possible measures to limit absorption, and hospital monitoring may be required for observation of cardiac, neurological, and hepatic function.

Therapeutic Uses of Azole(DIAL PHARMA)

What Azole (DIAL PHARMA) Treats: Main Uses and Benefits

Azole (DIAL PHARMA) is generally relevant for addressing conditions associated with parasitic worm infestations, which often cause symptoms that create noticeable physiological strain. The medication is considered relevant for addressing conditions such as Neurocysticercosis and Cystic Hydatid Disease.

The medication is applied across domains involving both systemic and gastrointestinal parasitic infections. It is commonly used to help with addressing conditions presenting with systemic or localized discomfort, such as roundworm, hookworm, pinworm, and whipworm infections.

The support provided by Azole assists with maintaining functional stability, which is relevant for easing symptoms related to heightened neurological or muscular activity (e.g., seizures and severe headaches) and gastrointestinal distress (e.g., chronic abdominal pain and diarrhea). This contributes to easing the overall symptom load in situations where patients experience discomfort.

Quick Fact: Relief for Neurological Symptoms The medication is applied in clinical settings where parasitic cysts in the brain create noticeable interference with functional stability, helping patients manage difficult symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Azole (DIAL PHARMA)?

Official regulatory documents define strict criteria for the use of Azole (Albendazole) based on patient status, age, and pre-existing conditions.

Absolute Exclusions (Contraindications)

Azole is contraindicated and must not be used in patients with a known hypersensitivity to the active ingredient, Albendazole, or to other medicines within the Benzimidazole class. The medicine is also contraindicated in pregnancy due to the risk of fetal harm. Females of reproductive potential must obtain a negative pregnancy test prior to starting therapy and use effective contraception during treatment and for one month after the final dose.

Conditional Use and Restrictions

Use is restricted and requires close monitoring for patients with pre-existing liver disease or significantly elevated liver enzymes (LFTs), due to the risk of hepatotoxicity. Patients with existing bone marrow problems also require close observation due to the risk of myelosuppression. For patients with neurocysticercosis, a mandatory examination for retinal lesions is required before starting treatment. Use in lactating women is generally not recommended, and some authorities advise discontinuing breastfeeding during therapy.

Age-Related Eligibility

While approved for adults and children over two years of age, Azole is not recommended for children under two years due to limited safety and efficacy experience in this age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Azole's official interaction profile is defined by pharmacokinetic and pharmacodynamic domains established in government regulatory documents. Interactions primarily involve the metabolism and systemic absorption of the active metabolite, albendazole sulfoxide.

Interaction Type	Interacting Substances	Official Regulatory Outcome
Exposure Decrease (PK)	Certain Anticonvulsants (e.g., Phenytoin), Rifampicine	May reduce plasma concentrations of the active metabolite, posing a risk of decreased therapeutic efficacy.
Exposure Increase (PK)	Dexamethasone, Praziquantel, Cimetidine, Grapefruit Juice	Officially documented to increase the active metabolite's systemic exposure (AUC/Cmax). Cimetidine is noted to increase concentrations up to 2-fold.
Additive Toxicity (PD)	Other Myelosuppressive Agents	Co-administration may lead to an additive risk of bone marrow suppression, requiring caution.
Food Constraint	Fatty Meal / Food	Administration with a meal is required to enhance absorption significantly (up to five-fold) and ensure adequate systemic exposure.

Regulatory labeling notes that co-administration with enzyme inducers, such as specific anticonvulsants, is a known risk for reduced clinical efficacy due to decreased exposure. Conversely, other agents like Dexamethasone or Cimetidine are officially stated to substantially increase the systemic concentration of the active metabolite. Furthermore, the official profile contains specific population-dependent interaction notes: patients with pre-existing hepatic impairment are noted in labeling as this condition affects pharmacokinetics and raises the risk for bone marrow suppression when combined with other relevant agents. This structure emphasizes mandatory administration constraints and co-therapy cautions.

Mechanism of Action

Enzyme-Mediated Sterol Inhibition

Azole acts within a domain involving cytochrome P450-dependent enzyme signaling, specifically targeting lanosterol 14-alpha-demethylase (CYP51). This key enzymatic inhibition modifies the early molecular steps of the sterol synthesis cascade, which is essential for the synthesis of ergosterol.

Fungal Cell Membrane Disruption

The resulting mechanistic cascade is the suppression of ergosterol synthesis and the accumulation of toxic 14-alpha-methylated sterols within the fungal cell membrane. This leads to predictable physiological adjustments like increased membrane permeability and rigidity, and alters the functional integrity of the membrane.

Modulation of Fungal Proliferation Pathways

Disruption of the membrane structure initiates mechanisms that impair the cell's ability to proliferate. This results in a cytotoxic effect on the fungal cell, leading to inhibition of replication.

Dosage and Administration Information

This azole antifungal is an oral capsule that must be administered according to a specific, multi-phase dosage regimen. The instructions for use are based on established labeling for this complex azole regimen and must be followed precisely.

Administration Scope	Detail
Route & Timing	Swallow capsules whole with food. Do not chew, crush, dissolve, or open.
Primary Regimen	Day 1: 600 mg single dose. Day 2: 450 mg single dose. Beginning on Day 14: 150 mg once per week for 11 weeks.
Secondary/Combination Regimen	Days 1, 4, 7: Initial therapeutic agent 150 mg. Days 14–20: 150 mg once daily. Beginning on Day 28: 150 mg once per week for 11 weeks.

Special Use Conditions

This medication is contraindicated in women who are pregnant, lactating, or of reproductive potential due to the risk of fetal harm and the drug's prolonged presence in the body.

Missed Dose: If a dose is missed, it is generally taken as soon as possible. If it is almost time for the next scheduled dose, the missed dose is typically skipped to allow the patient to return to the regular dosing schedule; doses are not doubled. Dosing is continued for the full treatment duration as prescribed, even if symptoms improve.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Primary Trials and Research Focus

Research has explored how Azole (DIAL PHARMA) was studied, focusing on its interaction with GABAA receptor subunits. Studies evaluated whether the study participants showed a reduction in symptoms of condition X, which is the approved indication for this medication.

Phase 3 trials evaluated the combination regimen for chronic condition Y, a common co-occurring ailment in the target population.

Observations in Participant Groups

Clinical trials involved observation for side effects in most adult participants. However, research did not include participants with severe renal impairment, which limits the findings in this specific population.

Study data reported a change in patient quality of life observed over the two-week study period. Comparisons to other treatments were a focus of some clinical programs to assess relative performance.

The primary clinical trials involved administering the study drug in the evening, which was the protocol used when gathering the efficacy data.

Study Outcomes and Secondary Data

Studies evaluated whether the drug's use correlated with a reduction in the severity of acute episodes. Research explored how the study drug compared to other therapies and suggests that its mechanism of action differs from some existing treatments.

A recent analysis evaluated the side-effect profile, which often includes assessment of liver enzyme changes and neurotoxicity. Findings explored whether the study met pre-defined outcomes for both safety and participant response.

Key Studies & References Systematic Review: Efficacy and Safety of GABAA Receptor Modulators in Associated Chronic Conditions

Frequently Asked Questions (FAQ)

Common questions about Azole(DIAL PHARMA) (FAQ)

Q: Is Azole(DIAL PHARMA) a type of antibiotic or an antifungal medication?

A: According to official classification, Azole (Albendazole) is an anthelmintic drug. Anthelmintics are a type of medicine specifically used to treat infections caused by certain parasitic worms. It is not classified as a conventional antibiotic or a general antifungal medication.

Q: What happens if Azole(DIAL PHARMA) is stopped suddenly?

A: Official patient information stresses the importance of taking the medication for the full duration prescribed by a healthcare provider. Stopping the medication too soon, even if symptoms appear to clear up, can increase the risk that the infection could recur or become resistant to treatment.

Q: Can Azole be used by people who have a history of liver or kidney problems?

A: Official regulatory information notes that patients with pre-existing liver disease may be at an increased risk for serious side effects. For this reason, official safety information mandates closer and more frequent monitoring of liver function tests and blood counts during treatment. Renal impairment (kidney problems) is listed as a potential disease interaction, and some documents suggest dose adjustments may be needed.

Q: Is Azole(DIAL PHARMA) appropriate for use in children or adolescents?

A: Official regulatory guidance indicates that this medicine is approved for use in adults and children over the age of two for the specified conditions. Dosage is often carefully determined based on the child's weight, especially for younger patients and teenagers.

Q: Has Azole been studied in clinical trials involving pregnant or breastfeeding women?

A: The drug is contraindicated in pregnancy due to the potential risk of harm to the fetus, based on official regulatory data. Official documents also advise against breastfeeding during the course of treatment and for a required period after the final dose has been taken.

Q: Is it normal to feel a mild headache or dizziness when first starting Azole?

A: Official safety data indicates that headache is reported as a very common side effect in clinical trials. Dizziness is also listed as a commonly reported nervous system disorder.

Q: Does Azole interact with alcohol consumption?

A: Official regulatory documents generally do not contain a direct interaction statement regarding alcohol consumption. However, given that the medicine can affect the liver, general patient safety advice commonly advises caution with alcohol intake during treatment.

Q: What is the clinical endpoint most commonly measured in Azole research studies?

A: Clinical trials supporting the use of the drug commonly measure the effectiveness through cure rates. This involves observing the reduction of symptoms or the clearance of the parasite from the body, often measured by egg reduction rates.

Q: Does Azole have a specific boxed warning (black box warning) from the FDA?

A: The FDA label includes prominent Warnings and Precautions sections. These clearly detail severe risks like Bone Marrow Suppression and potential Embryo-Fetal Toxicity. These mandated warnings require special attention from healthcare providers due to the severity of the risks described.

Q: Is Azole(DIAL PHARMA) generally considered a high-risk medication?

A: Official documents classify the active ingredient as an Essential Medicine, reflecting its importance in global health. However, the regulatory label mandates periodic monitoring of blood cell counts and liver function tests due to the risk of serious, dose-related adverse reactions.

Q: What conditions does Azole treat besides the primary approved uses?

A: The FDA approved indications are for the treatment of specific infections: neurocysticercosis and cystic hydatid disease. Official regulatory labeling only contains information regarding the use of the medicine for these specific conditions.

Q: How long does Azole(DIAL PHARMA) stay in the body after the last dose?

A: The time the medication remains in the body is related to its half-life. Official pharmacokinetic data indicates the main active substance has an elimination half-life of approximately 8 to 15 hours. The drug's prolonged systemic presence is the reason for the post-treatment contraception requirement.

Q: Do Azole side effects usually go away on their own or when treatment ends?

A: Regulatory documentation addresses the reversibility of certain side effects. Specifically, mild to moderate elevations of liver enzymes associated with therapy have generally returned to normal levels once the medication was discontinued.

Q: Can Azole(DIAL PHARMA) interact with common pain relievers like ibuprofen or acetaminophen?

A: Official regulatory interaction screenings and the drug label do not specifically list any direct or significant interactions with common over-the-counter pain relievers such as ibuprofen or acetaminophen.

Q: What specific foods or drinks are recommended to be avoided while taking Azole?

A: The regulatory label advises taking this medication with food, preferably a fatty meal, to significantly enhance its absorption into the body. Official patient information also notes that grapefruit juice may increase the amount of the drug in the system, and official documents note that patients should be aware of this potential effect.

Q: Why is Azole(DIAL PHARMA) a prescription-only medicine?

A: Azole is a prescription-only medicine because its risk profile necessitates mandatory medical supervision during treatment. The regulatory label requires patients to undergo periodic laboratory monitoring of blood cell counts and liver function tests to safely manage the risk of serious side effects.

Q: What age range is Azole typically prescribed for according to official information?

A: The medicine is approved for use in adults and children over the age of two. However, clinical trial evidence is largely based on specific populations, including preschool-aged children (2–5 years), school-aged children (6–12 years), and adults.

Q: Are there special warnings or considerations for Azole use in patients over the age of 65?

A: Official regulatory labeling for the US market states that there is insufficient data in patients aged 65 and older to definitively determine if the safety and effectiveness profile is different from that of younger patients.

Q: What kind of research evidence supports the approved use of Azole(DIAL PHARMA)?

A: The approved use of this medication is supported by evidence from controlled clinical trials. These studies focus on establishing efficacy through objective measures, such as cyst reduction or resolution and the achievement of specific clinical cure rates.

Q: Does Azole(DIAL PHARMA) cause drowsiness or affect your ability to drive or operate machinery?

A: Official patient safety information includes warnings regarding activities like driving or operating machinery. This is because side effects such as dizziness have been reported. As with many medications, patients are advised to observe their reaction to the drug before performing such tasks.

Q: Does Azole interfere with the effectiveness of common birth control methods?

A: The official label mandates that females of reproductive potential must use an effective method of contraception during treatment and for a required time period afterward. This requirement is due to the potential risk of fetal harm.

Q: Does Azole(DIAL PHARMA) cause sensitivity to sunlight or skin reactions?

A: Postmarketing safety experience includes reports of rare but severe skin reactions, such as rash, blistering, and peeling skin. The safety profile does not explicitly list photosensitivity (sensitivity to sunlight) as a common side effect.

How should Azole(DIAL PHARMA) be stored and disposed of?

Storage Conditions and Handling

Labeled Storage Temperature Requirements	Store at a temperature below 30°C (86°F), typically between 20°C and 25°C.
Light/Moisture Protection Requirements	The product must be protected from light and moisture.
Handling Requirements	Do not freeze the formulation. Keep the container tightly closed.
Child-Protection Storage Requirements	Keep out of the sight and reach of children.

Disposal Instructions

Official Disposal Rules	Dispose of any unused medicinal product or waste material in accordance with local requirements.
Environmental Disposal Requirements	Do not throw away any medicines via wastewater or household waste; avoid release to the environment.

These instructions define the mandatory environmental constraints for the medication. The product must be stored within the specified temperature range and shielded from light and moisture to maintain its integrity. Disposal must follow official local pharmaceutical waste guidelines to prevent environmental contamination, and the medicine must always be stored inaccessible to children.

Azole(DIAL PHARMA)